A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Phase 2 Completed 74 enrolled Bristol-Myers Squibb

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to determine the objective response rate in patients with relapsed or refractory Hodgkin's disease treated with MDX-060 in combination with gemcitabine or gemcitabine alone.

Timeline

Start: 2005-11
Primary completion: 2008-05
Completion: 2009-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	iratumumab	Monoclonal antibody	10 mg/kg	Intravenous

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Summary

Timeline

Drugs

Indications